BeiGene Operating Margin 2014-2024 | ONC
Current and historical operating margin for BeiGene (ONC) over the last 10 years. The current operating profit margin for BeiGene as of September 30, 2024 is -25.94%.
| BeiGene Operating Margin Historical Data |
| Date |
TTM Revenue |
TTM Operating Income |
Operating Margin |
| 2024-09-30 |
$3.32B |
$-0.87B |
-26.29% |
| 2024-06-30 |
$3.10B |
$-0.89B |
-28.62% |
| 2024-03-31 |
$2.76B |
$-1.10B |
-39.75% |
| 2023-12-31 |
$2.46B |
$-1.21B |
-49.15% |
| 2023-09-30 |
$2.20B |
$-1.29B |
-58.67% |
| 2023-06-30 |
$1.81B |
$-1.60B |
-88.18% |
| 2023-03-31 |
$1.56B |
$-1.72B |
-110.21% |
| 2022-12-31 |
$1.42B |
$-1.79B |
-126.25% |
| 2022-09-30 |
$1.25B |
$-1.89B |
-151.24% |
| 2022-06-30 |
$1.07B |
$-1.92B |
-179.23% |
| 2022-03-31 |
$0.88B |
$-1.95B |
-222.58% |
| 2021-12-31 |
$1.18B |
$-1.44B |
-122.36% |
| 2021-09-30 |
$1.06B |
$-1.35B |
-127.31% |
| 2021-06-30 |
$0.95B |
$-1.33B |
-140.44% |
| 2021-03-31 |
$0.86B |
$-1.21B |
-140.67% |
| 2020-12-31 |
$0.31B |
$-1.66B |
-536.57% |
| 2020-09-30 |
$0.27B |
$-1.56B |
-586.84% |
| 2020-06-30 |
$0.23B |
$-1.43B |
-636.89% |
| 2020-03-31 |
$0.40B |
$-1.16B |
-288.56% |
| 2019-12-31 |
$0.43B |
$-0.96B |
-224.30% |
| 2019-09-30 |
$0.43B |
$-0.85B |
-198.37% |
| 2019-06-30 |
$0.43B |
$-0.69B |
-159.45% |
| 2019-03-31 |
$0.24B |
$-0.77B |
-315.16% |
| 2018-12-31 |
$0.20B |
$-0.71B |
-354.77% |
| 2018-09-30 |
$0.16B |
$-0.53B |
-334.81% |
| 2018-06-30 |
$0.32B |
$-0.26B |
-81.17% |
| 2017-09-30 |
$0.22B |
$-0.03B |
-14.55% |
| 2016-12-31 |
$0.00B |
$-0.12B |
-11700.00% |
| 2016-03-31 |
$0.01B |
$-0.05B |
-757.14% |
| 2015-12-31 |
$0.01B |
$-0.04B |
-614.29% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$17.962B |
$2.459B |
|
BeiGene, Ltd. is a biotechnology company which focused on immuno-oncological therapeutics. The company's clinical-stage drug candidates include BGB-3111, BGB-283, BGB-290, and BGB-A317. BeiGene, Ltd. is based in Camana Bay, Cayman Islands.
|
